Tag: Johnson & Johnson

Court Ordered Johnson & Johnson to Pay $8bn

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could gr...

Johnson & Johnson Dedicated $500m to Eliminate HIV and Tuberculosis by 2030

JohnsonJohnson
Johnson & Johnson announced that it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accele...

J&J Announced Agreement with Ohio Counties Ahead of Upcoming Opioid Trial

JohnsonJohnson
Johnson & Johnson and its Janssen Pharmaceutical Companies announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties’ claims with no admissio...

J&J Stelara Approved in EU for Ulcerative Colitis

johnson & johnson
Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared...

J&J Announced Launch of Consortium to Discover and Develop New TB Antibiotics

tb
As part of the Company’s 10-year initiative to drive progress against tuberculosis (TB), Johnson & Johnson announced that it has launched an international research consortium to discover and devel...

U.S. Justice Department Pursue Investigation over Cancer Risk in J&J’s Powder

The U.S. Justice Department is pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder, people with knowledge of th...

Celsius and Janssen in Collaboration

Celsius Therapeutics announced a collaboration with Janssen Biotech. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify...

Johnson & Johnson Announced Results from the Phase 3 Study of XARELTO®

johnson&johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivar...

J&J’s INVOKANA Significantly Reduced Major Cardiovascular Events and Kidney Failure

johnson & johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new subgroup analysis from the landmark phase 3 CREDENCE study, showing INVOKANA® (canagliflozin) significantly red...

J&J Published Data from Phase 3 DARZALEX® Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...

J&J Used Underhanded Tactics to Fend Off Generics

Johnson & Johnson’s blockbuster cancer med Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to ke...

J&J Presented Early Results from First-In-Human Study of Monarch™ Platform

johnson & johnson
Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platf...

Janssen Submitted Application for ERLEADA Approval

johnson & johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approv...

Xarelto’s Sales Drop as Competition Pile Up

bayer
After a rough year for Bayer and Johnson & Johnson's anticoagulant Xarelto, the companies hoped the competition would take it easy in 2019. Pfizer and Bristol-Myers Squibb's Eliquis had other plan...

Johnson & Johnson Beats Estimates on Pharma Strength, Raises Sales Forecast

johnsonandjohnson
Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn’s disease and ca...

J&J Completes Acquisition of Auris Health

johnson & johnson
Johnson & Johnson announced that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, i...